Intelligence / Healthtech / De Novo Grants / Abbott Diabetes Care
Abbott Diabetes Care
25 Aug 2026: Novel device granted (FDA De Novo) · Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 25 Aug 2026
- Device
- Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System
- Specialty
- Clinical Chemistry
- Product Code
- SJD
- Country
- United States
- Location
- Alameda, CA
- Submitted
- 2025-09-29
- Reference
- DEN250049
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Find the decision makers at Abbott Diabetes Care
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Abbott Diabetes Care in our registers.
More in Clinical Chemistry
De Novo Grants
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.